Replimune

-$0.11 (-0.59%) Today

$0.00 (0.00%) As of 8:16 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3.

CEO

Philip Astley-Sparke

Employees

206

Headquarters

Woburn, Massachusetts

Founded

2015

REPL Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

367.52K

High today

$18.90

Low today

$17.55

Open price

$18.43

Volume

737.38K

52 Week high

$40.22

52 Week low

$13.05

REPL News

Simply Wall StJun 24

Replimune Group, Inc. Shares Could Be 23% Below Their Intrinsic Value Estimate - Simply Wall St

In this article we are going to estimate the intrinsic value of Replimune Group, Inc. ( ) by estimating the company's future cash flows and discounting them to

Analyst ratings

Buy

100%

Hold

Sell

REPL Earnings

-$1.75

-$1.17

-$0.58

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Estimated

— per share

Actual

Expected Aug 4, Pre-Market

Why Robinhood?

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. View more

Replimune Group, Inc. Shares Could Be 23% Below Their Intrinsic Value Estimate - Simply Wall St

100%

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3.